Vice President Marianne Cunnington to Speak at Inaugural European Summit for Women Leaders in Life Sciences Law
Event: European Summit for Women Leaders in Life Sciences Law Date: 11 March 2025 Host: C5 Group Location: Brussels, Belgium Times: 13:15–14:00 (GMT) / 14:15–15:00 (CET)
Vice President Marianne Cunnington will speak at the inaugural European Summit for Women Leaders in Life Sciences Law. The event will gather attorneys and executives from the biotech, pharmaceutical, and medical device industries to discuss emerging industry regulation and legal trends, as well as strategies for professional growth and career advancement.
Dr. Cunnington will join a panel discussing the impact of the EU’s new health technology assessment (HTA) regulation on market access. The panelists will examine the regulation’s directives and share insights on initial experience, implementation challenges, and opportunities, including with respect to evidence generation strategies. The other panelists include Ioana Ratescu (Novartis), Koosje van Lessen Kloeke (Leijnse Artz), and Eleanor Charsley (Office for Life Sciences).
Analysis Group is the luncheon sponsor of this event.
Associated People
Marianne Cunnington
Managing PrincipalDr. Cunnington specializes in regulatory epidemiology, including the design and execution of real-world post-marketing safety and effectiveness studies, as well as real-world studies to support the approval of new products through innovative regulatory pathways. Her research expertise includes design, negotiation, and execution of real-world components of risk management plans for new product submissions with regulators across multiple geographies (US, UK, Europe, Japan, South Korea); post-approval safety studies in the EU; post-marketing requirement and commitment studies in the US; and pregnancy registries. Prior to joining Analysis Group, Dr. Cunnington spent more than 20 years as a pharmaceutical industry epidemiologist focusing on the generation of real-world evidence (RWE) to support the development and life cycle management of vaccines and pharmacological therapies. Dr. Cunnington held several senior epidemiology positions within Novartis and GlaxoSmithKline (GSK). At GSK, she chaired the peer review forum for all pharmaceutical RWE projects, provided epidemiological expertise for the company’s Global Safety Board, and was a managing board member of the Innovative Medicines Initiative’s public-private partnership, building an integrated European real-world data network to monitor medication safety in pregnancy. Dr. Cunnington serves on the board of the International Society for Pharmacoepidemiology as an elected representative of European industry and service providers.